Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Leukemia drug appears to be effective in treating deadly pediatric brain tumor

A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego.

21 Sep 2019

Study opens a promising new front in the fight against pancreatic cancer

Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs.

19 Sep 2019

Researchers develop new cocktail of drugs that shrink pancreatic tumors

Cancer is relentless and resilient. When a drug blocks a cancer cell's main survival pathway, the cell avoids the obstacle by taking different pathways or detours to save itself. This tactic is called "developing resistance," and it's one of the key challenges researchers face when seeking effective therapeutics to combat pancreatic ductal adenocarcinoma (PDA).

9 Sep 2019

Updated ASGE guideline on screening and surveillance of Barrett's esophagus released

The American Society for Gastrointestinal Endoscopy has released its updated "ASGE guideline on screening and surveillance of Barrett's esophagus," published in the September issue of GIE: Gastrointestinal Endoscopy.

5 Sep 2019

Nerve cells aid in the spread of pancreatic cancer, study reveals

A couple of molecules that nerve cells use to grow during development could help explain why the most common pancreatic cancers are so difficult to contain and for patients to survive, a new study led by Johns Hopkins Kimmel Cancer Center researchers suggests.

30 Aug 2019

Researchers decode chain of molecules critical for growth and survival of pancreatic cancer

Researchers at Georgetown Lombardi Comprehensive Cancer Center have decoded a chain of molecules that are critical for the growth and survival of pancreatic ductal adenocarcinoma (PDAC)-;the most common and also the most lethal form of pancreatic cancer.

23 Aug 2019

Swallowable balloon device for early detection of Barrett's esophagus receives FDA 510K clearance

Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center developed the test for early detection of Barrett's esophagus that offers promise for preventing deaths from esophageal adenocarcinoma.

21 Aug 2019

Drug that treat human breast cancer might also work for canine lung cancer

Despite those velvet paintings of poker-playing dogs smoking pipes, cigars and cigarettes, our canine friends really don't use tobacco. But like many humans who have never smoked, dogs still get lung cancer.

21 Aug 2019

Study shows synergistic effects of drugs that inhibit cell division in pancreatic cancer

Pancreatic cancer is one of the deadliest cancers, with patients surviving on average less than a year once the disease has spread.

19 Aug 2019

Roswell Park receives more than $15 million in grants for cancer research

Roswell Park Comprehensive Cancer Center researchers have received more than a dozen recent grant awards totaling more than $15.4 million.

14 Aug 2019

Mice study suggests anti-cancer effect of ketogenic diet

It's well known that keeping blood glucose levels in check can help individuals avoid or manage diabetes, but new research led by biologists at The University of Texas at Dallas suggests that restricting blood glucose levels might also keep certain cancers at bay.

13 Aug 2019

Longer-lived, but less toxic drug may work better for pancreatic cancer

Unlike many other cancers, most pancreatic tumors are rock hard.

9 Aug 2019

New improved model for cancer wasting syndrome cachexia

A new model of cancer-related cachexia promises to help scientists understand why patients with cancer show severe wasting, which in turn may drive the development of better therapies.

7 Aug 2019

Research offers molecular details of pancreatic cancer's ability to invade and evade

Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.

6 Aug 2019

Discovery of distinct lung cancer pathways could help future patients

Known for its poor prognosis, lung adenocarcinoma is the most common type of lung cancer, responsible for about 4 of 10 diagnoses, according to the National Cancer Institute.

2 Aug 2019

Promising antibody therapy reduces tumor growth, increases survival in mice with pancreatic cancer

Scientists have found a way to target and knock out a single protein that they have discovered is widely involved in pancreatic cancer cell growth, survival and invasion.

31 Jul 2019

MGH researchers identify potential markers of lung cancer

By examining both blood samples and tumor tissues from patients with non-small-cell lung cancer, investigators at Massachusetts General Hospital have identified markers that can distinguish between major subtypes of lung cancer and can accurately identify lung cancer stage.

16 Jul 2019

Study could lead to new strategies for slowing the growth of glioblastoma

Researchers are hopeful that new strategies could emerge for slowing the growth and recurrence of the most common primary brain cancer in adults, glioblastoma, based on the results of a study published today in Cancer Research.

10 Jul 2019

Using molecular biomarkers to guide the choice of therapies for metastatic pancreatic cancer

A new pilot study demonstrated the feasibility of using molecular tumor markers as the basis for selecting the chemotherapeutic agents to use in patients with metastatic pancreatic cancer.

11 Jun 2019

Combination immunotherapy shows promise in pre-surgical setting for early-stage lung cancers

Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery.

3 Jun 2019